GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetron Holdings Ltd (NAS:GTH) » Definitions » Debt-to-EBITDA

Genetron Holdings (Genetron Holdings) Debt-to-EBITDA : -0.24 (As of Jun. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Genetron Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Genetron Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $16.72 Mil. Genetron Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $7.34 Mil. Genetron Holdings's annualized EBITDA for the quarter that ended in Jun. 2022 was $-101.31 Mil. Genetron Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2022 was -0.24.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Genetron Holdings's Debt-to-EBITDA or its related term are showing as below:

GTH's Debt-to-EBITDA is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.76
* Ranked among companies with meaningful Debt-to-EBITDA only.

Genetron Holdings Debt-to-EBITDA Historical Data

The historical data trend for Genetron Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetron Holdings Debt-to-EBITDA Chart

Genetron Holdings Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial - -0.11 -0.04 -0.17 -0.26

Genetron Holdings Quarterly Data
Dec17 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.16 -0.11 -0.12 -0.24 N/A

Competitive Comparison of Genetron Holdings's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Genetron Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetron Holdings's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetron Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Genetron Holdings's Debt-to-EBITDA falls into.



Genetron Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Genetron Holdings's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(18.822 + 3.922) / -89.178
=-0.26

Genetron Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(16.719 + 7.343) / -101.312
=-0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2022) EBITDA data.


Genetron Holdings  (NAS:GTH) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Genetron Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Genetron Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Genetron Holdings (Genetron Holdings) Business Description

Traded in Other Exchanges
N/A
Address
No. 8 Life Science Parkway, 1-2nd Floor, Building 11, Zone 1, Changping District, Beijing, CHN, 102206
Genetron Holdings Ltd is an oncology company in China. It is specialized in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The company's operating segment includes Diagnosis and monitoring - provision for LDT services; Diagnosis and monitoring - sale of IVD products and Development services. It generates maximum revenue from the Diagnosis and monitoring - provision for LDT services segment.